Synergistic effects of GSK-3β and HDAC inhibitors in intracerebroventricular streptozotocin-induced cognitive deficits in rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 388, Issue 3, 2015, Pages 337-349

  Sharma, Sorabh ^a   Taliyan, Rajeev ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Alzheimer's disease; GSK 3 ; Histone deacetylases; Intracerebroventricular; Oxidative stress; Streptozotocin

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; LITHIUM CHLORIDE; NITRITE; STREPTOZOCIN; VALPROIC ACID; ACETYLCHOLINESTERASE; GLYCOGEN SYNTHASE KINASE 3; HISTONE DEACETYLASE INHIBITOR; MALONALDEHYDE; NEUROPROTECTIVE AGENT; NITRIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; BRAIN NERVE CELL; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; LEARNING; LOCOMOTION; LOW DRUG DOSE; MEMORY CONSOLIDATION; MEMORY DISORDER; MORRIS WATER MAZE TEST; NEUROPROTECTION; NONHUMAN; PASSIVE AVOIDANCE; PROTEIN BLOOD LEVEL; RAT; SPATIAL LEARNING; ANIMAL; ANTAGONISTS AND INHIBITORS; AVOIDANCE BEHAVIOR; BRAIN; CHEMICALLY INDUCED; COGNITION DISORDERS; DRUG COMBINATION; DRUG EFFECTS; MEMORY; MEMORY DISORDERS; METABOLISM; PATHOLOGY; WISTAR RAT;

ACETYLCHOLINESTERASE; ANIMALS; AVOIDANCE LEARNING; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION DISORDERS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GLUTATHIONE; GLYCOGEN SYNTHASE KINASE 3; HISTONE DEACETYLASE INHIBITORS; INSULIN; LITHIUM CHLORIDE; MALONDIALDEHYDE; MEMORY; MEMORY DISORDERS; NEUROPROTECTIVE AGENTS; NITRATES; NITRITES; RATS, WISTAR; SPATIAL LEARNING; STREPTOZOCIN; VALPROIC ACID;

EID: 84925461107     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-014-1081-2     Document Type: Article

References (68)

1. Agrawal R, Tyagi E, Shukla R, Nath C (2009) A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia. Neuropharmacology 56:779-787
2. Arabpoor Z, Hamidi G, Rashidi B, Shabrang M, Alaei H, Sharifi MR, Salami M, Dolatabadi HR, Reisi P (2012) Erythropoietin improves neuronal proliferation in dentate gyrus of hippocampal formation in an animal model of Alzheimer's disease. Adv Biomed Res 1:50
3. Arancibia S, Silhol M, Mouliere F, Meffre J, Hollinger I (2008) Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol Dis 31:316-326
4. Bardai FH, D'Mello SR (2011) Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3β. J Neurosci 31:1746-1751
5. Bhat RV, Budd Haeberlein SL, Avila J (2004) Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 89:1313-1317
6. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW (2004) Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 101:2173-2178
7. Caberlotto L, Carboni L, Zanderigo F, Andreetta F, Andreoli M, Gentile G, Razzoli M (2013) Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system. Naunyn Schmiedebergs Arch Pharmacol 386:893-903
8. Chiu CT, Liu G, Leeds P, Chuang DM (2011) Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology 36:2406-2421
9. Craft S, Watson GS (2004) Insulin and neuro-degenerative disease: shared and specific mechanisms. Lancet Neurol 3:169-178
10. Cui J, Shao L, Young LT, Wang JF (2007) Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 144:1447-1453
11. Dash PK, Orsi SA, Zhang M, Grill RJ, Pati S, Zhao J, Moore AN (2010) Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PLoS One 5(6):e11383
12. De la Monte SM, Wands JR (2005) Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis 7:45-61
13. Deshmukh R, Sharma V, Mehan S, Sharma N, Bedi KL (2009) Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine-A PDE1 inhibitor. Eur J Pharmacol 620:49-56
14. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70-77
15. Ellman GL, Courtney KD, Andres V, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95
16. Feng HL, Leng Y, Ma CH, Zhang J, Ren M, Chuang DM (2008) Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neurosci 155:567-572
17. Frey BN, Valvassori SS, Reus GZ, Martins MR, Petronilho FC, Bardini K, Dal-Pizzol F, Kapczinski F, Quevedo J (2006) Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 31:326-332
18. Göttlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978
19. Green LC, Wagner DA, Glgowski J, Skipper PL, Wishnok JS, Tannebaum SR (1982) Analysis of nitrate, nitrite and [15 N] nitrate in biological fluids. Ann Biochem Exp Med 126:131-135
20. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83:4913-4917
21. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, Nieland TJ, Zhou Y, Wang X, Mazitschek R, Bradner JE, DePinho RA, Jaenisch R, Tsai LH (2009) HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459:55-60
22. Khan MB, Khan MM, Khan A, Ahmed ME, Ishrat T, Tabassum R, Vaibhav K, Ahmad A, Islam F (2012) Naringenin ameliorates Alzheimer's disease (AD)-type neurodegeneration with cognitive impairment (AD-TNDCI) caused by the intracerebroventricular-streptozotocin in rat model. Neurochem Int 61:1081-1093
23. Klein PS, Melton DA (1996) Molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93:8455-8459
24. Kumar A, Sharma S, Prashar A, Deshmukh R (2014) Effect of licofelone-a dual COX/5-LOX inhibitor in intracerebroventricular streptozotocin-induced behavioral and biochemical abnormalities in rats. J Mol Neurosci. doi: 10.1007/s12031-014-0414-4
25. Laske C, Stransky E, Leyhe T, Eschweiler GW, Wittorf A, Richartz E, Bartels M, Buchkremer G, Schott K (2006) Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm 113:1217-1224
26. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, Chuang DM (2008) Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 28:2576-2588
27. Leroy K, Yilmaz Z, Brion JP (2007) Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 33:43-55
28. Lindvall O, Kokaia Z, Bengzon J, Elmér E, Kokaia M (1994) Neurotrophins and brain insults. Trends Neurosci 17:490-496
29. Loscher W, Fisher JE, Nau H, Hönack D (1989) Valproic acid in amygdala-kindled rats: alterations in anticonvulsant efficacy, adverse effects and drug and metabolite levels in various brain regions during chronic treatment. J Pharmacol Exp Ther 250:1067-1078
30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
31. Lubin FD, Roth TL, Sweatt JD (2008) Epigenetic regulation of BDNF gene transcription in the consolidation of fear memory. J Neurosci 28:10576-10586
32. Mangialasche F, Polidori MC, Monastero R, Ercolani S, Camarda C, Cecchetti R (2009) Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Aging Res Rev 8:285-305
33. Markesbery RS, Kamat PK, Nath C, Shukla R (2012) A study on neuroinflammation and NMDA receptor function in STZ (ICV) induced memory impaired rats. J Neuroimmunol 254:1-9
34. Marlatt MW, Lucassen PJ, Perry G, Smith MA, Zhu X (2008) Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies. J Alzheimers Dis 15:199-210
35. McQuown SC, Barrett RM, Matheos DP, Post RJ, Rogge GA, Alenghat T, Mullican SE, Jones S, Rusche JR, Lazar MA, Wood MA (2011) HDAC3 is a critical negative regulator of long-term memory formation. J Neurosci 31:764-774
36. Mesulam MM, Asuncion Moran M (1987) Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease. Ann Neurol 22:223-228
37. Miranda MI, Ferreira G, Ramirez-Lugo L, Bermudez-Rattoni F (2003) Role of cholinergic system on the construction of memories: taste memory encoding. Neurobiol Learn Mem 80:211-222
38. Morris RGM (1984) Development of a water-maze procedure for studying spatial learning in the rats. J Neurosci Methods 11:47-60
39. Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C (2010) Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 469:6-10
40. Pappolla MA, Chyan YJ, Omar RA, Hsiao K, Perry G, Smith MA, Bozner P (1998) Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 152:871-877
41. Parr C, Carzaniga R, Gentleman SM, Van Leuven F, Walter J, Sastre M (2012) Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-β precursor protein. Mol Cell Biol 32:4410-4418
42. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic, San Diego
43. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I (1997) Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 56:70-78
44. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734-36741
45. Phiel CJ, Wilson CA, Lee VM, Klein PS (2003) GSK-3 alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423:435-443
46. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA (1991) BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7:695-702
47. Plaschke K, Kopitz J, Siegelin M, Schliebs R, Salkovic-Petrisic M, Riederer P, Hoyer S (2010) Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. J Alzheimers Dis 19:691-704
48. Ponce-Lopez T, Liy-Salmeron G, Hong E, Meneses A (2011) Lithium, phenserine, memantine and pioglitazone reverse memory deficit and restore phospho-GSK3β decreased in hippocampus in intracerebroventricular streptozotocin induced memory deficit model. Brain Res 1426:73-85
49. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273:32730-32738
50. Rai S, Kamat PK, Nath C, Shukla R (2012) A study on neuroinflammation and NMDA receptor function in STZ (ICV) induced memory impaired rats. J Neuroimmunol 254:1-9
51. Rees T, Hammond PI, Soreq H, Younkin S, Brimijoin S (2003) Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol Aging 24:777-787
52. Ren M, Senatorov VV, Chen RW, Chuang DM (2003) Post-insult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci U S A 100:6210-6215
53. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM (2004) Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 89:1358-1367
54. Ryves JW, Dalton EC, Harwood AJ, Williams RS (2005) GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid. Bipolar Disord 7:260-265
55. Sereno L, Coma M, Rodriguez M, Sanchez-Ferrer P, Sanchez MB, Gich I, Agullo JM, Perez M, Avila J, Guardia-Laguarta C, Clarimón J, Lleo A, Gomez-Isla T (2009) A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis 35:359-367
56. Shao L, Young LT, Wang JF (2005) Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 58:879-884
57. Sharma M, Gupta YK (2003) Effect of alpha lipoic acid on intracerebroventricular streptozotocin model of cognitive impairment in rats. Eur Neuropsychopharmacol 13:241-247
58. Sharma S, Taliyan R (2014) Neuroprotective role of Indirubin-3'-monoxime, a GSKβ inhibitor in high fat diet induced cognitive impairment in mice. Biochem Biophys Res Commun 452:1009-1015
59. Sharma V, Bala A, Deshmukh R, Bedi KL, Sharma PL (2012) Neuroprotective effect of RO-20-1724-a phosphodiesterase4 inhibitor against intracerebroventricular streptozotocin induced cognitive deficit and oxidative stress in rats. Pharmacol Biochem Behav 101:239-245
60. Sharma S, Kumar K, Deshmukh R, Sharma PL (2013) Phosphodiesterases: regulators of cyclic nucleotide signals and novel molecular target for movement disorders. Eur J Pharmacol 714:486-497
61. Sharma S, Taliyan R, Ramagiri S (2014). Histone deacetylase inhibitor, trichostatin A, improves learning and memory in high-fat diet-induced cognitive deficits in mice. J Mol Neurosci. doi: 10.1007/s12031-014-0461-x
62. Shonesy BC, Thiruchelvam K, Parameshwaran K, Rahman EA, Karuppagounder SS, Huggins KW, Pinkert CA, Amin R, Dhanasekaran M, Suppiramaniam V (2012) Central insulin resistance and synaptic dysfunction in intracerebroventricular-streptozotocin injected rodents. Neurobiol Aging 33:5-18
63. Siegel GJ, Chauhan NB (2000) Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Brain Res Rev 33:199-227
64. Su Y, Ryder J, Li B, Wu X, Fox N, Solenberg P, Brune K, Paul S, Zhou Y, Liu F, Ni B (2004) Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 43:6899-6908
65. Sun X, Sato S, Murayama O, Murayama M, Park JM, Yamaguchi H, Takashima A (2002) Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett 321:61-64
66. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ (2000) Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci 20:1657-1665
67. Wills ED (1996) Mechanism of lipid peroxide formation in animal. Biochem J 99:667-676
68. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM (2009) The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 14:51-59